MIBHS
MARCH 31, 2025
When discussing heart health, heart attacks and cardiac arrest are two terms that are often mistaken for one another. While both are serious medical emergencies, they are not the same condition. Understanding the difference between heart attack and cardiac arrest can help in recognizing symptoms, seeking prompt medical care, and even saving lives. What is a Heart Attack?
American College of Cardiology
MARCH 31, 2025
Sotatercept, a first-in-class novel activin-signaling inhibitor, led to a 76% lower risk of a composite of death from any cause, lung transplantation or hospitalization for worsening pulmonary arterial hypertension (PAH) compared to placebo in high-risk adults with PAH, according to results from the ZENITH study presented during a Clinical and Investigative Horizons session at ACC.25 in Chicago and simultaneously published in NEJM.
ADN Center of Excellence
MARCH 31, 2025
In the continuously evolving world of healthcare, keeping up with the latest findings, technologies, and best practices is vital for medical professionals. One of the most effective ways to do this is through conferences that focus on medical education. These events are not just a way to earn continuing education credits; they are foundational to shaping how healthcare providers learn and apply knowledge in their practices.
American College of Cardiology
MARCH 31, 2025
Coronary atherosclerotic phenotypes, including total plaque volume (TPV), noncalcified plaque (NCP), calcified plaque (CP) and percentage atheroma volume (PAV), assessed by artificial intelligence-based quantitative coronary computed tomography (AI-QCT) conferred a higher relative risk of major adverse cardiovascular events (MACE) in women, based on findings from the CONFIRM II trial presented at ACC.25 in Chicago and simultaneously published in Circulation: Cardiovascular Imaging.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
DAIC
MARCH 31, 2025
tim.hodson Mon, 03/31/2025 - 10:26 March 31, 2025 AGEPHA Pharma USA, LLC, has released clinical data that provides new information about how low-dose colchicine, 0.5 mg reduces the risk of major adverse cardiovascular events (MACE) and supports its use in the treatment of cardiovascular disease. The study, Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients With Stable Coronary Artery Disease Compared To Placebo: The Ekstrom Trial, was presented at the American Col
American College of Cardiology
MARCH 31, 2025
AZD0780, a novel, once-daily oral molecule inhibitor, had a robust, dose-dependent effect in lowering LDL-C and a favorable safety profile in patients with hypercholesterolemia already on background moderate- or high-intensity statin treatment, according to research presented during a Featured Clinical Research session at ACC.25 in Chicago and simultaneously published in JACC.
Cardiovascular Update brings together the best content for cardiovascular medicine professionals from the widest variety of industry thought leaders.
American College of Cardiology
MARCH 31, 2025
Among patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and chronic kidney disease (CKD), the baseline estimated glomerular filtration rate (eGFR) did not impact the effect of tirzepatide on reducing major adverse HF events or to enhance health status, according to a post-hoc analysis of the SUMMIT trial presented during a Featured Clinical Research session at ACC.25 in Chicago and simultaneously published in JACC.
DAIC
MARCH 31, 2025
tim.hodson Mon, 03/31/2025 - 15:39 March 30, 2025 Medtronic has announced late-breaking data on five-year outcomes from the Evolut Low Risk Trial. Data shows, versus surgery, the Evolut transcatheter aortic valve replacement (TAVR) system delivers a numerically lower rate of all-cause mortality or disabling stroke at five years, strong valve performance and durable clinical outcomes.
American College of Cardiology
MARCH 31, 2025
Angiopoietin-like 3 (ANGPTL-3) inhibition with the human monoclonal antibody, SHR-1918, reduces serum LDL-C by 22% to 30%, as well as triglyceride (TG) levels by 52% to 63%, in patients at moderate or higher risk of atherosclerotic cardiovascular disease (ASCVD), with the effect being dose and frequency dependent, according to research presented during a Clinical and Investigative Horizons session at ACC.25 in Chicago and simultaneously published in JACC.
DAIC
MARCH 31, 2025
tim.hodson Mon, 03/31/2025 - 15:02 March 31, 2025 iRhythm Technologies, Inc. has announced results from two large real-world retrospective analyses presented at the American College of Cardiology (ACC) 2025 Scientific Sessions in Chicago. Drawing on data from more than 1.1 million patients who used iRhythms Ziolong-term continuous monitoring (LTCM) ECG devices, these studies demonstrate that short-term (2448-hour) monitoring, such as with Holter devices, fails to detect a significant proportion
HCPLive
MARCH 31, 2025
Panelists discuss how systemic treatments for moderate to severe atopic dermatitis offer significant advantages over topicals, including more comprehensive disease control, improved adherence, reduced treatment burden, greater efficacy for widespread disease, ability to address immunological drivers of inflammation, prevention of flares, management of both cutaneous and extracutaneous manifestations, reduced corticosteroid exposure, and potential modification of disease trajectoryparticularly be
American College of Cardiology
MARCH 31, 2025
Refocusing and reframing the definition and discussion of coronary artery disease (CAD) from late-stage ischemia and acute coronary events to early detection of coronary artery atheroma and prevention of advanced acute coronary syndrome (ACS) has the potential to save 8.7 million lives globally every year, according to a new report from The Lancet Commission presented at ACC.25.
HCPLive
MARCH 31, 2025
Panelists discuss how the approval of dupilumab and subsequent biologics for moderate to severe atopic dermatitis has fundamentally transformed the treatment landscape by providing targeted, effective options with favorable safety profiles that address underlying disease pathways, shifting from symptomatic management toward long-term disease control, raising expectations for treatment outcomes, reducing reliance on systemic immunosuppressants, enabling personalized therapy based on specific infl
AMS Cardiology
MARCH 31, 2025
Atrial fibrillation (AFib) is a common heart rhythm disorder characterized by an irregular and often rapid heartbeat. This condition can lead to various complications, including stroke and heart failure, making it essential to understand its causes, symptoms, and AFib treatment options. Consulting a local cardiologist is crucial for the proper diagnosis and management of AFib.
CTVS
MARCH 31, 2025
An estimated 700,000 sternotomies are performed annually in the United States. It is a serious surgery that opens up the chest cavity through the breastbone, or sternum, to gain access to the lungs and heart.
Science Daily - Heart Disease
MARCH 31, 2025
New research reveals that lower proportions of specific sleep stages are associated with reduced brain volume in regions vulnerable to the development of Alzheimer's disease over time.
Med Page Today
MARCH 31, 2025
(MedPage Today) -- Three days of intermittent fasting (IMF) each week was a bit better for weight loss than daily caloric restriction (DCR), the DRIFT randomized trial found. Over 12 months, participants who restricted their energy intake by 80.
HCPLive
MARCH 31, 2025
Mantzoros explains the need for multidisciplinary MASLD care and how to balance lifestyle modifications with emerging medications.
Med Page Today
MARCH 31, 2025
(MedPage Today) -- CHICAGO -- Novel small interfering RNA (siRNA) agent lepodisiran drastically cut levels of lipoprotein(a), or Lp(a), in the phase II ALPACA trial. The 400-mg dose cut Lp(a) by 93.9 percentage points compared with placebo from.
HCPLive
MARCH 31, 2025
Hosts break down the STRIDE and SOUL trial results and reflect on how they might inform treatment strategies in the respective patient populations.
Med Page Today
MARCH 31, 2025
(MedPage Today) -- Prenatal use of smoking cessation therapies was not linked to increased risks of major congenital malformations (MCMs) compared with smoking during the first trimester, a retrospective cohort study suggested. Compared with unexposed.
Science Daily - Heart Disease
MARCH 31, 2025
A trial of 648 patients found that the new automated method and intervention strategy resulted in nearly four times as many diagnoses and treatment plans for high blood pressure compared with traditional office-based health care visits.
American College of Cardiology
MARCH 31, 2025
It is my great honor to serve this wonderful community as your 76th president. I would like to start by congratulating all of you who are receiving your FACC and AACC designations today.
Med Page Today
MARCH 31, 2025
(MedPage Today) -- The number of U.S. adults without diabetes using GLP-1 receptor agonists more than tripled from 2018 to 2022, boosting annual spending from $1.6 billion to $5.8 billion, survey data showed. Based on an unweighted sample of nearly.
NEJM Journal Watch - Cardiology
MARCH 31, 2025
In a phase 2 manufacturer-funded trial, lepodisiran safely reduced Lp(a) levels in a dose-dependent manner.
Med Page Today
MARCH 31, 2025
(MedPage Today) -- Scientists have developed a device that can translate thoughts about speech into spoken words in real time. Although it's still experimental, they hope the brain-computer interface could someday help give voice to those unable.
HCPLive
MARCH 31, 2025
Justin Mark, MD, discusses an analysis of the FIGHT trial looking at racial and ethnic differences in heart failure outcomes.
American College of Cardiology
MARCH 31, 2025
The goal of the Altshock-2 trial was to evaluate the effect of early intra-aortic balloon pump (IABP) use vs. standard care on 60-day survival or successful bridging to heart replacement therapies (HRT) in patients with heart failurecardiogenic shock (HF-CS).
HCPLive
MARCH 31, 2025
The Biologics License Application submission for sibeprenlimab is supported by results from the phase 2 ENVISION and phase 3 VISIONARY clinical trials.
American College of Cardiology
MARCH 31, 2025
Solbinsiran at the 400 mg dose reduced apolipoprotein B (apoB) concentration in patients with mixed dyslipidemia, according to research presented during a Featured Clinical Research session at ACC.25 in Chicago and simultaneously published in The Lancet.
HCPLive
MARCH 31, 2025
A study links daily discrimination to greater depression and anxiety rates, with marginalized groups facing greater mental health risks across the US.
NEJM Journal Watch - Cardiology
MARCH 31, 2025
Low-intensity apixaban was not judged less effective than full-intensity apixaban and resulted in fewer clinically relevant bleeding events.
HCPLive
MARCH 31, 2025
Jose Lopez, MD, discusses findings and perspective into racial and ethnic differences in DbCM from the ARISE-HF trial.
Journal of Cardiothoracic Surgery
MARCH 31, 2025
Blunt thoracic aortic injury (BTAI) is a critical clinical emergency often presenting as severe trauma. The early diagnosis and treatment of BTAI pose significant challenges in its management, especially when.
HCPLive
MARCH 31, 2025
These data on patients in Japan demonstrate positive efficacy and safety findings in real-world settings, with uniquely positive results among bio-nave patients.
Cardiovascular Ultrasound
MARCH 31, 2025
To analyze the echocardiography characteristics of pulmonary artery sling (PAS) and explore the diagnostic value of the distance between the bifurcation of the left and right pulmonary arteries and the pulmona.
Expert insights. Personalized for you.
52 
Let's personalize your content